Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00478634
Status:
COMPLETED
Last Update Posted:
2012-11-02
First Post:
2007-05-24
Brief Title:
A Phase 1 Study Investigating the Combination of RAD001 Cetuximab and Irinotecan as Second-line Therapy After FOLFOX or XELOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-label Multicenter Phase 1 Study Investigating the Combination of RAD001 Cetuximab and Irinotecan as Second-line Therapy After FOLFOX or XELOX Plus Bevacizumab if Given as Part of Local Standard Practice in Patient With Metastatic Colorectal Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None